TEL AVIV, Israel & ZURICH, & NEW YORK--(BUSINESS WIRE)--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ('SHL' or the 'Company'), a leading provider and developer of advanced personal telemedicine solutions, is thrilled to announce that it recently officially launched it’s SmartHeart® membership program in the US..

以色列特拉维夫、苏黎世和纽约——（商业新闻短讯）——SHL远程医疗有限公司（纳斯达克股票代码：SHLT，SIX股票代码：SHLTN；）（“SHL”或“公司”）是先进个人远程医疗解决方案的领先提供商和开发商，很高兴宣布它最近在美国正式推出了SmartHeart®会员计划。。

This announcement comes after the highly successful soft launch that was announced in November 2023, which exceeded the company's expectations, demonstrating substantial demand and positive customer feedback.

这一宣布是在2023年11月宣布的非常成功的软发布之后发布的，该发布超出了公司的预期，显示出巨大的需求和积极的客户反馈。

Erez Nachtomy, CEO of SHL Telemedicine commented: 'The official launch marks a significant milestone in our mission to transform cardiac care accessibility. The overwhelming success of our soft launch has not only validated the demand for accessible, at-home cardiac care but also underscored the effectiveness of our solutions in enhancing heart health management.'.

SHL Telemedicine首席执行官Erez Nachtomy评论道：“此次正式推出标志着我们转变心脏护理可及性的使命中的一个重要里程碑。我们软启动的巨大成功不仅验证了对可获得的家庭心脏护理的需求，而且强调了我们的解决方案在加强心脏健康管理方面的有效性。”。

This official launch is further bolstered by the recent, positive results from a clinical study conducted with Imperial College London, which demonstrated significant reductions in hospital readmissions and emergency department visits among post-ACS patients using the SmartHeart® system, underlining its effectiveness and transformative potential in remote cardiac care..

最近与伦敦帝国理工学院（Imperial College London）进行的一项临床研究取得了积极的结果，这进一步支持了这项正式启动，该研究表明，使用SmartHeart®系统的ACS后患者的再住院率和急诊就诊率显着降低，突显了其在远程心脏护理中的有效性和变革潜力。。

Jason Bottiglieri, General Manager of SHL Telemedicine USA added: “This launch marks a pivotal moment for healthcare accessibility in the U.S. The SmartHeart® membership brings medical expertise directly into our customers' homes, enhancing their ability to manage heart health proactively. Our technology and service are not just about responding to symptoms but empowering users to take control of their cardiac health with unprecedented ease and confidence.”.

SHL Telemedicine USA总经理Jason Bottiglieri补充道：“此次发布标志着美国医疗保健可及性的关键时刻。SmartHeart®会员将医疗专业知识直接带到我们客户的家中，增强了他们主动管理心脏健康的能力。我们的技术和服务不仅是为了应对症状，还让用户能够以前所未有的轻松和自信控制自己的心脏健康。”。

The SmartHeart® membership is a private pay program designed to revolutionize home-based access to cardiac care. It includes the innovative, user-friendly SmartHeart® portable 12-lead ECG device, offering round-the-clock interpretation by board-certified cardiologists and on-demand telehealth visits.

SmartHeart®会员是一项私人付费计划，旨在彻底改变家庭获得心脏护理的方式。它包括创新的、用户友好的SmartHeart®便携式12导联心电图设备，提供由董事会认证的心脏病专家进行的全天候解读和按需远程医疗访问。

This initiative not only simplifies the process of conducting a full 12-lead ECG at home but also ensures convenient and dependable heart health management, meeting the evolving needs of today's healthcare consumers..

这一举措不仅简化了在家中进行全12导联心电图的过程，而且确保了方便可靠的心脏健康管理，满足了当今医疗保健消费者不断变化的需求。。

SmartHeart® Membership Offers:

SmartHeart®会员资格提供：

Portable 12-lead ECG Device: The SmartHeart® ECG, a cutting-edge and user-friendly device, enables high-quality 12-lead ECG performance anytime and anywhere.

便携式12导联心电图设备：SmartHeart®ECG是一款尖端且用户友好的设备，可随时随地实现高质量的12导联心电图性能。

24/7 Cardiologist Interpretation: Subscribers have access to expert analysis of their ECG by board-certified cardiologists, offering peace of mind and prompt response to cardiac symptoms.

24/7心脏病专家解释：订阅者可以通过董事会认证的心脏病专家对他们的心电图进行专家分析，从而提供安心和对心脏症状的迅速反应。

On-demand Telehealth Visits: Subscribers can easily access medical professionals for consultations, enabling timely and informed health decisions.

按需远程医疗访问：订阅者可以轻松访问医疗专业人员进行咨询，从而及时做出明智的健康决策。

For detailed information on subscription options and availability of the SmartHeart® Membership program in different states, as well as customer testimonials, please visit our website at www.getsmartheart.com.

有关SmartHeart®会员计划在不同州的订阅选项和可用性以及客户证明的详细信息，请访问我们的网站www.getsmartheart.com。

About SHL Telemedicine

关于SHL远程医疗

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology.

SHL Telemedicine致力于开发和销售个人远程医疗系统，并为最终用户和医疗保健界提供医疗呼叫中心服务，重点是心血管疾病和相关疾病。SHL远程医疗利用电话和互联网通信技术为用户提供服务和个人远程医疗设备。

SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200)..

SHL在六家瑞士交易所（SHLTN，ISIN:IL0010855885，证券号：1128957）和纳斯达克证券交易所（SHLT，ISIN:US78423T2006，CUSIP:78423T200）上市。。

For more information, please visit our website at www.shl-telemedicine.com.

有关更多信息，请访问我们的网站www.shl-telemedicine.com。

Forward-Looking Statements

前瞻性声明

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors.

本新闻稿中的一些信息包含前瞻性声明。读者应注意，任何此类前瞻性陈述都不能保证未来的表现，并涉及风险和不确定性，由于各种因素，实际结果可能与前瞻性陈述中的结果存在重大差异。

SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements..

SHL远程医疗不承担公开更新或修改任何前瞻性声明的义务。。